The dynamic nature of the COVID-19 crisis has drastically transformed the medical instrument industry landscape. Through the nearly two-year-long healthcare emergency, this industry has been swinging back and forth between crisis and opportunities. Despite the full-fledged vaccine rollouts, industry watchers are still unable to gauge the magnitude of economic revival due to the emergence of new and more contagious strains in several parts of the world including the United States.
A number of medical instrument companies, which had confirmed a gradual rebound in their base businesses earlier in 2021, are once again seeing staffing shortage and supply-chain related hazards in the past couple of months, thanks to the emergence of the Omicron variant, which has been identified by WHO, as a variant of concern. Meanwhile, industry players that have well-adapted to changing consumer preference or have a COVID-19-based businesses like Thermo Fisher Scientific Inc. TMO, STERIS plc STE and Accuray ARAY are still witnessing a continued uptrend in their stock prices.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
Accuray Incorporated (ARAY): Free Stock Analysis Report
STERIS plc (STE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
